Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting clinical results from a German study using PET/CT and its radiohybrid prostate-specific membrane antigen-targeted compound for prostate cancer.
Researchers from the Technical University of Munich presented study results at the American Urological Association's 2020 virtual meeting. A group led by Dr. Tobias Maurer found that F-18 PET/CT results using the compound, called rhPSMA-7.3, showed sensitivity of 81%, specificity of 88%, and diagnostic accuracy of 86% in 56 patients with intermediate or high-risk prostate cancer when compared with histopathological results.
These results have been included in Blue Earth's investigational new drug submission to the U.S. Food and Drug Administration.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
